上交所深夜火速出手！两科创板公司被监管警示

Core Viewpoint - The article discusses regulatory warnings issued by the Shanghai Stock Exchange to two companies, Yahui Long and Yingjixin, for inaccurate and incomplete disclosures related to their "brain-computer interface" business, highlighting the importance of accurate information disclosure in a market with heightened investor interest in this sector [1][4][5]. Group 1: Regulatory Actions - On January 7, the Shanghai Stock Exchange issued regulatory warnings to Yahui Long and Yingjixin due to their misleading disclosures regarding their involvement in the "brain-computer interface" sector [1][4]. - Both companies received inquiries from the exchange on January 6, prompting them to clarify their business risks and provide additional disclosures [2][4]. Group 2: Market Reactions - The "brain-computer interface" concept has become a market hotspot, leading to significant stock price increases for several companies, including Weisi Medical, Xiangyu Medical, and Mcland, which experienced consecutive trading halts [3][8]. - Yahui Long's stock rose by 6.52% on January 6, with trading volume increasing by 299% compared to the previous day, following the announcement of a strategic cooperation framework with Shenzhen Brain Star Chain Technology Co., Ltd. [4]. Group 3: Information Disclosure Issues - Yahui Long's announcement regarding its cooperation with Brain Star Chain was criticized for being vague and inconsistent, failing to adequately disclose the risks associated with its business [5][6]. - Yingjixin's communication on its IPA1299 chip, intended for brain-computer interface applications, was also deemed insufficient, lacking clarity on the product's market status and potential sales uncertainties [5][6]. Group 4: Broader Industry Context - Other companies in the sector, such as Weisi Medical, Xiangyu Medical, and Mcland, have also issued announcements to clarify their positions and remind investors of the risks associated with their involvement in the "brain-computer interface" market, emphasizing that their main business remains in rehabilitation medical devices [8]. - The article notes that the technology paths for these companies are primarily "non-invasive," contrasting with the "invasive" approaches taken by leading international firms in the field [8].